Lee Schwartzberg, Md, On Oneoncology Embracing Car-T And Policies To Prevent Financial Toxicity

Lee Schwartzberg, MD, on OneOncology embracing CAR-T and policies to prevent financial toxicity

Dr Lee Schwartzberg on How Biosimilars Will Help Address Financial Toxicity

Dr Lee Schwartzberg Reflects on the First Year of OneOncology

Lee Schwartzberg MD, shares exciting initiatives in the works in his role at OneOncology

Lee Schwartzberg, MD, describes how OneOncology is blazing a trial in clinical trial accrual

Dr Lee Schwartzberg: How OneOncology Will Help Community Practices Navigate Cancer Care Landscape

Toxicity Management for CAR-T

CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24

HealthTree Foundation for Multiple Myeloma

Investigating production failure and out-of-specification production of CAR T-cell therapeutics

VJHemOnc – Video Journal of Hematology & HemOnc

ASH 2024: Ziad Abuhelwa, MD on Patterns & Outcomes in Myeloma After Anti-BCMA CAR T Therapy

Moffitt Cancer Center

Day 1 round up: CAR-T toxicity

VJHemOnc – Video Journal of Hematology & HemOnc

Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors

The major hurdles of CAR-T cell therapy for solid tumors

Dr. Tanya Dorff on The Future of CAR T Cell Therapy for Prostate Cancer | ASCO22

Dr Lee Schwartzberg: There's Still an Education Gap for Biosimilars

Lee Schwartzberg, MD, explains technology assistance as the Chief Medical Officer for OneOncology

Identifying patient subgroups to improve outcome, resistance and toxicity in CAR T

VJHemOnc – Video Journal of Hematology & HemOnc

Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman | #ASH24

HealthTree Foundation for Multiple Myeloma

Early Identification of Toxicity & Responses to BCMA CAR-T Therapy in RRMM | Kai Rejeski, MD |#ASH24

HealthTree Foundation for Multiple Myeloma

CAR T-Cell Therapy